Skip to main content
. Author manuscript; available in PMC: 2018 Feb 21.
Published in final edited form as: Virology. 2016 Jun 15;496:147–165. doi: 10.1016/j.virol.2016.06.005

Fig 6. Sensitivity of VEEV mutants to a pre-established anti-viral state.

Fig 6

(A) Vero cells were mock-treated or treated with 5000 IU human leukocyte IFN for 24h before infection in triplicate with indicated viruses (M.O.I. = 2.5). Supernatants were collected at 12h and 24h p.i. and virus replication was quantified using plaque assays. For each virus, data represents fold change in titer over no IFN. ****, P<0.0001 using One-way ANOVA. Ns = not significant. Data is representative of two independent experiments. All error bars are standard deviations. (B) Tet-inducible mouse embryonic fibroblasts (MEFs) stably expressing IFIT1, ISG20 and GFP (control) were infected in triplicate with indicated viruses (M.O.I. = 1). Cell lysates were collected at 24h p.i and viral RNA levels were measured using RT PCR as described in Materials and Methods. Data represent viral RNA levels from IFIT1 or ISG20 expressing cells as a fold change of viral RNA levels from GFP expressing cells. ***, P<0.0002; **, P<0.006; *, P<0.05 using One-way ANOVA. All error bars are standard deviations.

HHS Vulnerability Disclosure